Table 2.
Summary of each data set used in the re-analysis and the number of differentially expressed pathways.
| Studies | Number of patients | Number of controls | Number of genes after preprocessing | Number of pathways have genes ≥ 10 | Up-regulated pathways | Down-regulated pathways |
| Ovarian Data Sets | ||||||
| Eyster | 6 | 6 | 3105 | 171 | 24 | 31 |
| Hever | 10 | 10 | 1930 | 139 | 56 | 59 |
| Roth | 18 | 23 | 2575 | 154 | 36 | 44 |
| Peritoneal Data Sets | ||||||
| Eyster | 5 | 5 | 3084 | 171 | 57 | 11 |
| Hull | 9 | 9 | 1255 | 113 | 29 | 7 |
| Uterine cycle Data Sets | ||||||
| Burney_Pro | 6 | 5 | 1900 | 138 | 4 | 3 |
| Burney_ES | 6 | 3 | 1471 | 122 | 12 | 21 |
| Burney_MS | 9 | 8 | 952 | 93 | 0 | 22 |
| Human endometrial endothelial cells Data Set | ||||||
| Sha | 5 | 5 | 2324 | 153 | 44 | 1 |
Pro, Proliferative; ES, early secretory; MS, midsecretory Proliferative